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Aims: To investigate whether high glucose induces myo-inositol oxygenase (MIOX) expression in periph-
eral blood mononuclear cells through transcription factors, nuclear factor of activated T cells 5 (NFAT5)
and carbohydrate response element binding protein (ChREBP), which may contribute to the pathogenesis
of diabetic nephropathy.
Methods: 34 patients with type 1 diabetes mellitus (20 with nephropathy, 14 without complications) and
9 healthy controls were recruited in this study. Peripheral blood mononuclear cells were exposed to nor-
mal, high glucose conditions with/without an aldose reductase inhibitor (ARI), using electrophoretic
mobility shift assays the DNA-binding activities of NFAT5 and ChREBP to corresponding sites in the pro-
moter region of MIOX gene were analysed. The protein levels and the enzyme activity of MIOX were mea-
sured.
Results: DNA-binding activities of NFAT5 and ChREBP were increased under high glucose conditions and
decreased in the presence of the ARI in all groups. In the presence of ARI, the DNA-binding activities of
NFAT5 and ChREBP were signiﬁcantly decreased by 41% (NFAT5: 0.91 ± 0.06 vs. 1.54 ± 0.12; p = 0.01)
and 49% (ChREBP: 0.92 ± 0.08 vs. 1.81 ± 0.22; p = 0.001) compared with high glucose in patients with
nephropathy. ARI treatment decreased the protein levels of MIOX under high glucose conditions in
patients with nephropathy (0.81 + 0.19 vs. 1.3 + 0.04; p = 0.049).
Summary/conclusions: There was a trend for increased binding activities of NFAT5 and ChREBP accompa-
nied with increased protein levels under high glucose, particularly in patients with nephropathy. ARI
treatment prevented these increases and this effect was more obvious in the patients with nephropathy
compared to the uncomplicated subjects.
 2010 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction
It has been widely accepted that long-term exposure to high
blood glucose plays an important role in the development of dia-
betic nephropathy [1]. High glucose, together with increased ﬂux
through the polyol pathway causes myo-inositol (MI) depletion
which may have a role to play in the development of diabetic
nephropathy. However, the mechanism of MI depletion is still un-
clear. It has been proposed that myo-inositol oxygenase (MIOX)
plays a key role in causing the depletion of MI.
There are two enzymes in the polyol pathway, aldose reductase
(AKR1B1) and sorbitol dehydrogenase. Together, they convert glu-ellitus. Published by Elsevier Ltd.
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Ocose to fructose via sorbitol. Under physiological conditions, most
of the cellular glucose is phosphorylated into glucose 6-phosphate,
and only a minor portion is metabolised through the polyol path-
way. However, high glucose conditions may saturate the enzymes
involved in the phosphorylation of glucose, and as a result, one-
third of intracellular glucose enters the polyol pathway, which
causes an accumulation of sorbitol within cells. Accumulation of
sorbitol is accompanied by a depletion of MI, and this alters
Na+/K+ ATPase activity and impairs phosphatidylinositol syntheses,
which is a common precursor of important secondary signalling
molecules. Several studies have shown that MI depletion is
associated with diabetic nephropathy, retinopathy, neuropathy
and diabetic cataracts [2–7]. MIOX is the ﬁrst and rate-limiting en-
zyme in the MI metabolism pathway, which is the glucuronate–
xylulose pathway and is the only pathway for MI catabolism. It
has been shown that an increase in MIOX enzyme activity is in
proportion to serum glucose concentrations [8]. Therefore, MIOXpen access under CC BY-NC-ND license.
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complications.
MIOX is predominantly expressed in the kidney, nerves and li-
ver [9–12]. The promoter region of both the human and murine
MIOX genes contain osmotic response element(s) (OREs) and car-
bohydrate response element(s) (ChREs). The binding activities of
the nuclear factor of activated T cells 5 (NFAT5) and carbohydrate
response element binding protein (ChREBP) to OREs and ChREs,
respectively, signiﬁcantly increase under high glucose conditions
[8,13]. High glucose and osmolytes signiﬁcantly increase the tran-
scriptional activity of MIOX by in vitro luciferase assays. Further-
more, increased MIOX expression has been shown in the kidneys
of diabetic mice [8]. In preliminary experiments, we have shown
that human peripheral blood mononuclear cells (PBMCs) express
the MIOX gene by a direct sequencing of reverse transcriptase
polymerase chain reaction (RT-PCR) products and Western blot-
ting. In related studies, we have shown that NFAT5 is involved in
the regulation of AKR1B1 under high glucose conditions [14] and
in the presence of an aldose reductase inhibitor (ARI), the binding
activities of nuclear factor kappa B (NFjB) [15] and NFAT5 (unpub-
lished data) to OREs in the promoter of the AKR1B1 gene were sup-
pressed. Therefore, our hypotheses are that high glucose increases
MIOX protein levels and activity which might be regulated through
increased binding activities of NFAT5 to OREs and ChREBP to ChREs
in the promoter region of the MIOX gene. These binding activities
may be different in the PBMCs from patients with nephropathy,
compared to those without complications. Inhibition of AKR1B1
may suppress MIOX protein levels and activity through reducing
the production of sorbitol through the polyol pathway.
To the best of our knowledge, there has been no study that has
investigated the factors involved in the regulation of the MIOX
gene and enzyme activity in patients with type 1 diabetes mellitus
(T1D) and nephropathy. Therefore, the aims of this study were to
investigate the regulation of MIOX expression under high glucose
conditions in the PBMCs from patients with T1D, with or without
nephropathy.2. Materials and methods
2.1. Subjects
The following Caucasoid subjects were included in this study:
34 patients with T1D and 9 ethnically matched healthy controls.
All patients with T1D as deﬁned by The Expert Committee On
The Diagnosis And Classiﬁcation Of Diabetes Mellitus [16] had at-
tended the Diabetes Clinic, Derriford Hospital, Plymouth. The study
was approved by the Local Research Ethical Committee, and in-
formed consent was obtained from all subjects. The criteria for dia-
betic microvascular complications have been published previously
[17].
2.1.1. Uncomplicated
Patients (n = 14) have been diagnosed with T1D for at least
20 years but remain free of retinopathy (fewer than ﬁve dots or
blots per fundus), proteinuria (urine Albustix negative on at least
three consecutive occasions over 12 months) and neuropathy
(overt neuropathy was deﬁned if there was any clinical evidence
of peripheral or autonomic neuropathy).
2.1.2. Diabetic nephropaths
Patients (n = 20) have had T1D for at least 8 years with persis-
tent proteinuria (urine Albustix positive on at least three consecu-
tive occasions over 12 months or three consecutive total urinary
protein excretion rates >0.5 g/24 h) in the absence of hematuria
or infection on midstream urine samples. Diabetic nephropathywas always associated with retinopathy. Retinopathy was deﬁned
as more than ﬁve dots or blots per eye; hard or soft exudates, new
vessels, or ﬂuorescein angiographic evidence of maculopathy or
previous laser treatment for pre-proliferative or proliferative reti-
nopathy; and maculopathy or vitreous haemorrhage. Fundoscope
was performed by both a diabetologist and an ophthalmologist.2.2. Cell isolation and cultures
Peripheral venous blood samples (20 ml) were collected into 5%
EDTA Vacutainers (Becton Dickinson, UK). The peripheral blood
mononuclear cells (PBMCs) were separated by using Histopaque
(Sigma, Dorset, UK) and grown in RPMI 1640 supplemented with
D-glucose at a concentration of 5.5 mmol/l, 10% calf serum and
2 mmol/l L-glutamine, 100 units/ml penicillin G sodium and
100 mg/ml streptomycin sulfate with PHA-P at a concentration of
5 lg/ml in a 37 C incubator with a controlled, humidiﬁed atmo-
sphere of 95% air/5% CO2. The cells were divided into three groups
in 200 ml-ﬂasks. Group 1 (normal conditions-NG): cells were cul-
tured in the above medium (D-glucose at a ﬁnal concentration of
5.5 mmol/l). Group 2 (high glucose conditions-HG): 19.5 mmol/l
extra D-glucose was added into above-mentioned media (D-glucose
at a ﬁnal concentration of 25 mmol/l). Group 3 (aldose reductase
inhibitor conditions (ARI) with HG): sorbinil (at a ﬁnal concentra-
tion of 10 lmol/l), was added 3 h later after 19.5 mmol/l extra D-
glucose was added to the media. All cells were incubated for
5 days. At the end of the incubation time, cells were harvested
and nuclear and cytoplasmic proteins were extracted as below.2.3. Extraction of nuclear protein and cytoplasmic proteins
Cells were collected and re-suspended in 100 ll of buffer A
(10 lmol/l HEPES, pH 7.9, 1.5 mmol/l MgCl2, 0.5 mmol/l dithio-
threitol (DTT), 0.2% NP-40, 100 mmol/l 4-(2-aminoethyl)-bez-
enesulfonyl ﬂuoride (AEBSF), 18.4 mg/ml sodium orthovanadate,
42 mg/ml sodium ﬂuoride and 2.2 mg/ml aprotonin) and held on
ice for 15 min. The resulting cell lysate was then centrifuged at
13,000 rpm for 10 min. The supernatant containing cytoplasmic
proteins was transferred into a fresh tube and stored at 80 C
for Western blotting and MIOX activity assays. The nuclear pellets
were re-suspended in 50 ll of buffer C (20 mmol/l HEPES pH 7.9,
25% glycerol, 0.42 mol/l NaCl, 1.5 mmol/l MgCl2, 0.5 mmol/l DTT,
0.2 mmol/l EDTA, 100 mmol/l AEBSF, 18.4 mg/ml sodium ortho-
vanadate, 42 mg/ml sodium ﬂuoride and 2.2 mg/ml aprotonin),
and incubated on ice for 10 min. After centrifugation at
13,000 rpm for 10 min the supernatant containing the nuclear pro-
tein was transferred into a fresh tube and stored at80 C until use
in the electrophoretic mobility shift assay (EMSA). The concentra-
tions of both nuclear and cytoplasmic proteins were determined
using a Coomassie Plus Protein Assay kit (Peribo Science Ltd.,
Chest, UK).2.4. Electrophoretic mobility shift assay
NFAT5 and ChREBP probes with consensus sequence to the OER
and ChRE motifs CCTCCTCCAGGAAAGCCTTTACCCTCC and GAG-
CACGTGACCTACCCGTGTTG GGACACGTGAGG [8,13] of the MIOX
gene were labeled with [a-32P] deoxy-ATP by T4 polynucleotide ki-
nase (Amersham Pharmacia Biotech, Buckinghamshire, UK). The la-
beled probes along with the gel-binding buffer were incubated
with 25 lg of nuclear proteins at room temperature for 20 min.
The binding mixtures were resolved by electrophoresis on a 4%
non-denaturing polyacrylamide gel at 100 V for 3–4 h. The gel
was exposed to X-Omax photographic paper.
Table 1







Male:Female 6:14 4:10 4:5
Age (years) 49.6 ± 13.9
(30–82)
48.1 ± 14.9 (19–
74)
31.5 ± 5.14 (26–
41)
Age at onset of 12.3 ± 8.8 (1– 15.2 ± 9.4) (2– –
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All of the cytoplasmic proteins from each individual within each
group was pooled together and 50 lg of this was loaded onto a 7.5
or 10% precast SDS–PAGE (BIO-RAD Laboratory Ltd., Hempstead,
UK), electrophoresed for 2–3 h at 100 V and then transferred to
nitrocellular membrane (Amersham, USA) overnight. Next, the
membrane was blocked with 5% non-fat milk and 0.05% Tween
20-PBS for 1 h at room temperature. Immunoblotting was per-
formed with a primary goat antibody against human MIOX (Insight
Biotechnology Ltd., Wembley, UK) in a 1:500 dilution. Secondary
antibody against goat IgG of horse-radish peroxidase-conjugated
was used in 1:5000 dilution (Sigma, UK). A chemiluminescence
kit (Pierce, UK) and Kodak X-Omax ﬁlm (Amersham, UK) were used
to detect the amount of protein. In order to have equal amounts of
proteins loaded in wells, a-tubulin levels were measured using a
mouse antibody against human a-tubulin in 1:5000 dilution (Sig-
ma, UK) and a secondary antibody against mouse IgG of horse-rad-
ish peroxidase-conjugated in 1:5000 dilution (Sigma, UK).
DNA-binding activities of NFAT5 and ChREBP and protein levels
of MIOX were analysed and quantiﬁed using a phosphoimager
(BIO-RAD, UK) with multi-analyst software. All results were ex-
pressed as means of fold increase, due to high glucose treatment,
calculated by dividing the density in high glucose-treated cells
by the density in untreated cells, or as a mean fold decrease due
to ARI treatment, calculated by dividing the density in high glucose










12.7 ± 0.5 11.0 ± 0.4 –
HbA1c (%) 7.9 ± 0.1 8.4 ± 0.1 –
eGFR (mls/min/
1.73 m2)
59.4 ± 4.5* 74.5 ± 3.2 –
Data are means ± SE (ranges) in years. Levels of plasma, Haemoglobin A1c (HbA1c)
and estimated glomerular ﬁltration rate (eGFR) are expressed as means + SE in
mmol/l, % and mls/min/1.73 m2, respectively. Diabetic nephropaths, uncomplicated
and normal controls were deﬁned in Section 2.1.
* Vs. the uncomplicated, p = 0.02.
Nephropath Uncomplicated 







b2.6. MIOX activity assay
Pooled cytoplasmic proteins from each subject group were used
to perform MIOX enzyme activity by following the methods used
by Prabhu’s group [13]. Two-hundred and ﬁfty microgram of cyto-
plasmic proteins was mixed with 50 mM sodium acetate buffer
(pH 6.0), 2 mM L-cysteine, 1 mM ferrous ammonium sulfate and
with 60 mM of MI or without MI as a negative control and paral-
leled tubes with D-glucuronic acid as positive controls. The mixture
then was incubated at 30 C for 1 hour and the reaction was termi-
nated by the addition of 100 ll of 25% trichloroacetic acid. The
products, D-glucuronic acid in the supernatant was determined
by orcinol reagent [13,18,19]. Brieﬂy, 200 mg of orcinol were dis-
solved in 81.4 ml of concentrated HCl and then 2 ml of 2% ferric
chloride was added in. The ﬁnal solution was made up to 100 ml
with H2O. This solution must be made fresh. Two millilitre of the
orcinol reagent was then added into the reaction tubes, which then
were incubated at 100 C in a water bath for 30 min. After they
were cooled down to room temperature, 200 ll was transferred
into 96-well-microplates in triplicates and D-glucuronic acid was
measured on a spectrophotometer (GENios, Tecan, UK) at a wave-
length of 650 nm. The MIOX enzyme activity was normalized by
the activity without MI in the incubation reaction tubes. MIOX en-
zyme activities were expressed as mean of fold increase due to
high glucose treatment, calculated by dividing the optical density
(OD) value in high glucose-treated cells by the OD value in un-
treated cells or as mean of fold decrease due to ARI treatment, cal-
culated by dividing the OD value in high glucose with ARI-treated
cells by the OD value in high glucose-treated cells.NG  HG  ARI+HG         NG    HG  ARI+HG               NG    HG   ARI+HG 
Fig. 1. NFAT5: nuclear factor of activated T cell 5; ChREBP: carbohydrate response
element binding protein; NG: cells were cultured under normal conditions
(D-glucose at a ﬁnal concentration of 5.5 mmol/l). HG: cells were cultured under
high glucose conditions (D-glucose at a ﬁnal concentration of 25 mmol/l). ARI + HG:
cells were cultured under high glucose conditions with aldose reductase inhibitor,
sorbinil (at a ﬁnal concentration of 10 lmol/l).2.7. Statistical analysis
Data were analysed through SPSS. t-test, or one-way analysis of
variance (ANOVA) was used to test DNA-binding activities, MIOX
protein level, and MIOX enzyme activity between different groups.
A value of p < 0.05 was considered to be statistically signiﬁcant.3. Results
Clinical characteristics of patients with T1D with or without
diabetic nephropathy are shown in Table 1. There were no differ-
ences in age, gender, age at onset of diabetes, duration of diabetes,
Haemoglobin A1c (Hb1Ac) and plasma glucose levels between the
two groups. Estimated glomerular ﬁltration rate (eGFR) was signif-
icantly lower in patients with nephropathy compared with uncom-
plicated subjects (59.4 ± 4.5 vs. 74.5 ± 3.2; p = 0.021).
The DNA-binding activities of NFAT5 to the ORE and ChREBP to
the ChRE motifs in PBMCs exposed to either normal glucose, high
glucose or, ARI with high glucose conditions, from nephropaths,
uncomplicated and normal control subjects are shown in Fig. 1a
and b. DNA-binding activities of NFAT5 and ChREBP to their motifs
increased under high glucose conditions in all study groups; how-
ever, these increases did not reach statistical signiﬁcance. ARI
treatment signiﬁcantly decreased the DNA-binding activities of
Table 2
DNA-binding activities of NFAT5 and ChREBP to the ORE and ChRE in the promoter of the MIOX gene; MIOX protein levels and MIOX enzyme activity in patients with T1D with
diabetic nephropathy or uncomplicated and normal controls.
Stress Nephropaths (n = 20) Uncomplicated (n = 14) Normal controls (n = 9)
DNA binding
ChREBP to ChRE HG/NG 1.81 ± 0.22 (n = 11)* 1.30 ± 0.15 (n = 8) 1.41 ± 0.18 (n = 8)
ARI + HG/HG 0.92 ± 0.08 (n = 11) 0.92 ± 0.15 (n = 8) 0.95 ± 0.21 (n=8)
NFAT5 to ORE HG/NG 1.54 ± 0.12 (n = 13)# 1.20 ± 0.10 (n = 8) 1.24 ± 0.10 (n = 9)
ARI+HG/HG 0.91 ± 0.06 (n = 13) 1.13 ± 0.24 (n = 8) 0.90 ± 0.06 (n = 9)
MIOX proteins HG/NG 1.3 ± 0.04 [n = 6]§ 1.03 ± 0.04 [n = 4] 1.16 ± 0.56 [n = 3]
ARI + HG/HG 0.81 ± 0.19 [n = 6] 0.85 ± 0.05 [n = 4] 0.73 ± 0.12 [n = 3]
MIOX activity HG/NG 1.1 ± 0.4 [n = 3] 1.1 ± 0.1 [n = 3] 0.9 ± 0.1 [n = 3]
ARI + HG/HG 0.8 ± 0.1 [n = 3] 1.0 ± 0.4 [n = 3] 1.2 ± 0.3 [n = 3]
Abbreviations: NFAT5, nuclear factor of activated T cell 5; ChREBP, carbohydrate response element binding protein; MIOX, myo-inositol oxygenase; ORE, osmotic response
element; ChRE, carbohydrate response element.
NG: cells were cultured under normal conditions (D-glucose at a ﬁnal concentration of 5.5 mmol/l). HG: cells were cultured under high glucose conditions (D-glucose at a ﬁnal
concentration of 25 mmol/l). ARI + HG: cells were cultured under high glucose conditions with aldose reductase inhibitor, sorbinil (at a ﬁnal concentration of 10 lmol/l).
The density value was deﬁned as 1 under NG conditions. Data are expressed as means of fold changes ± SE under HG compared to NG conditions (HG/NG) or under the ARI
with HG conditions compared to HG conditions without ARI (ARI + HG/HG) in peripheral blood mononuclear cells from subjects with diabetic nephropathy or uncomplicated
and normal controls.
Sample sizes in the gel shift assay are shown within parentheses. The subjects in the electrophoretic mobility shift assays were overlapped. Pooled cytoplasmic proteins from
each subject group were used to perform Western blotting for measuring levels of MIOX protein and an assay for determining MIOX enzyme activity. Results are shown
herein from 3 to 6 independent measurements (square brackets).
* Vs. nephropaths under ARI + HG conditions (p = 0.001).
# Vs. nephropaths under ARI + HG conditions (p = 0.01).
§ Vs. nephropaths under ARI + HG conditions (p = 0.049).
Nephropath  
    ARI+HG       
Uncomplicated   Normal control   
MIOX   
α-tubulin   
      ARI+HG       NG         HG    NG           HG  NG              HG        ARI+HG       
Fig. 2. MIOX: myo-inositol oxygenase; NG: cells were cultured under normal conditions (D-glucose at a ﬁnal concentration of 5.5 mmol/l). HG: cells were cultured under high
glucose conditions (D-glucose at a ﬁnal concentration of 25 mmol/l). ARI + HG: cells were cultured under high glucose conditions with aldose reductase inhibitor, sorbinil (at a
ﬁnal concentration of 10 lmol/l).
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p = 0.01) and ChREBP to the ChRE motif by 49% (1.81 ± 0.22 vs.
0.92 ± 0.08, p = 0.001) in the nephropaths (Table 2). However, the
fold decrease due to ARI in the binding activities of NFAT5 and
ChREBP were not signiﬁcantly different in DN compared to the
uncomplicated group (NFAT5: 0.91 ± 0.06 vs. 1.13 ± 0.24, p > 0.05;
ChREBP: 0.92 ± 0.08 vs. 0.92 ± 0.15; p > 0.05) (Table 2). Further-
more, in the presence of ARI, the protein levels of MIOX were de-
creased in patients with nephropathy and this decrease just
reached statistical signiﬁcance (1.3 + 0.04 vs. 0.81 + 0.19;
p = 0.049). Again, the fold decrease in the MIOX protein levels
was not signiﬁcant between patients with nephropathy and the
uncomplicated group (0.81 + 0.19 vs. 0.85 + 0.05; p > 0.05) (Table
2, Fig. 2). Furthermore, the DNA-binding activities of NFAT5 and
ChREBP are correlated within individuals (data not shown), when
there is an increase in DNA binding of NFAT5 there is also in-
creased DNA binding of ChREBP.
MIOX enzyme activity was assessed by an orcinol reagent.
There was no signiﬁcant difference of MIOX enzymatic activity un-
der different conditions and between all study groups (Table 2).4. Discussion
There is considerable evidence that altered inositol metabolism
(MI depletion) due to hyperglycaemia is associated with microvas-
cular complications in both T1D and T2D [2–7]. A decreased uptake
rate of MI under high glucose conditions has been suggested to
contribute to MI depletion, seen in diabetes and its complicationsthrough both competitive (its stereochemical similarity between
D-glucose and MI) and non-competitive mechanisms (sorbitol
accumulation as a result of increased ﬂux of polyol pathway)
[20]. Evidence supporting the non-competitive mechanism is the
fact that the ARI signiﬁcantly ameliorated the decrease in MI up-
take. This suggests a close link between MI depletion and the pol-
yol pathway. Recent studies on the MIOX gene structure provided
another possible mechanism by which MI levels are regulated in
the cells. MIOX catalysis is the ﬁrst committed step in the glucuro-
nate–xylulose pathway, which is the only pathway for MI metabo-
lism. As the expression of the MIOX gene is ORE and ChRE-
dependent, its expression levels may be regulated by NFAT5 and
ChREBP under high glucose conditions [8]. The glucuronate–xylu-
lose pathway can also provide xylulose 5-phosphate, a cellular sen-
sor that activates ChREBP during hyperglycaemia [21]. Therefore,
high glucose may not only directly cause increased DNA-binding
activity of ChREBP to ChRE, but also the end product, xylulose 5-
phosphate, provides a positive feedback loop on MIOX expression.
In this study, we have demonstrated that high glucose induced the
binding activities of NFAT5 and ChREBP to ORE and ChRE in the
MIOX gene, respectively, although, these increases were not statis-
tically signiﬁcant. This trend may suggest that high glucose is in-
volved in the regulation of MIOX gene expression. However,
these increases were much higher in patients with nephropathy,
and were also accompanied by an increase in MIOX protein levels.
These results are similar to our previous studies, which have
shown that the DNA-binding activity of NFAT5/NFjB to ORE/jB
motif in the promoter region of AKR1B1 [14,15] is increased in
PBMCs from patients with T1D and nephropathy, compared to
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more, our previous studies have shown that mRNA and protein lev-
els of AKR1B1 and sorbitol dehydrogenase were increased in
PBMCs from patients with T1D and nephropathy [14,22]. These re-
sults clearly indicated that the response to uptake and metabolism
of D-glucose is different for patients with T1D and with or without
nephropathy. The exact mechanisms have still to be elucidated and
explored, but genetic associations such as AKR1B1 or glucose
transporter 1 (GLUT1) gene polymorphisms, may contribute to
the differences in gene expression [23,24]. Interestingly, there are
single nucleotide polymorphisms close to the OREs in the MIOX
gene. This could be another possible factor affecting MIOX expres-
sion levels through altered DNA-binding activity. A recent study
conducted in a renal tubule cell line [25] showed an increase in
MIOX mRNA and protein levels in the kidney of rats with diabetic
nephropathy, whilst also demonstrating that in vitro high glucose
signiﬁcantly increased MIOX secretion in rat renal tubular epithe-
lial cells, suggesting that hyperglycaemia may be a direct cause of
the MIOX increase in the kidney.
In diabetic complications, increased glucose levels are associ-
ated with high sorbitol accumulation in the kidney, nerve, retina,
and lens followed by a depletion of MI [2,3,5]. The MI metabolic
pathway is a source of xylitol, which would contribute to the in-
crease in AKR1B1 expression during hyperglycaemia. This could
establish another positive feedback loop on MIOX expression. Con-
sequently, the application of an ARI could decrease MIOX expres-
sion through the possible involvement of sorbitol in the process
of the DNA-binding of NFAT5 and ChREBP to the MIOX promoter,
as we showed in our study. In the presence of the ARI, sorbinil,
the DNA-binding activities of NFAT5 and ChREBP to ORE and ChRE
in the MIOX gene as well as MIOX protein levels were decreased
and these decreases were especially noticeable in patients with
nephropathy. These results support the evidence that an increased
ﬂux through the polyol pathway is involved in diabetic complica-
tions, and the accumulation of sorbitol produced by the increased
activity of AKR1B1 is linked to the expression of MIOX. ARIs have
been shown to improve MI uptake under high glucose conditions.
This suggests that the depletion of MI results from a glucose-in-
duced decrease in MI uptake, which is associated with increased
AKR1B1 enzyme activity [26,27]. Our ﬁndings, together with those
reported in cell lines and human neutrophils [28] strongly suggest
that the increased expression and activity of AKR1B1 is intricately
linked with the activation of MIOX. It has been suggested that the
inhibitors of MIOX could be of therapeutic value. Several studies
have demonstrated the therapeutic potential of inositol adminis-
tration [29–31], which suggested that regulation of MI levels
may represent a useful strategy. Inhibition of MIOX, as the ﬁrst en-
zyme in the only known pathway for inositol catabolism, should
raise inositol levels in diabetes, and may thus help counteract
hyperglycaemia.
The absence of any signiﬁcant detectable changes in MIOX en-
zyme activity in our subjects is disappointing, and may be due to
a number of reasons including the assay itself. Most assays done
by other groups have been on homogeneous MIOX enzyme ob-
tained from a centrifuged homogenate of rat or hog kidneys. There
is no publication to our knowledge that describes the MIOX assay
in PBMCs. Although, our RT-PCR (data not shown) and Western
blotting demonstrated that PBMCs expressed high levels of MIOX,
MIOX enzyme activity may not be very high in these cases. On the
other hand, the assay may not be sensitive and speciﬁc enough to
detect MIOX activity in the PBMCs extracted from our subjects pre-
pared in our way.
In summary, we have shown a trend for high glucose-increased
binding activities of NFAT5 and ChREBP accompanied with in-
creased protein levels, particularly in patients with nephropathy.
ARI treatment prevented these increases, and this effect was moreobvious in the patients with nephropathy, compared to the uncom-
plicated subjects. Our results suggested that NFAT5 and ChREBP
may be involved in the regulation of MIOX expression under high
glucose conditions in patients with T1D with nephropathy and that
sorbitol may be involved in the process of DNA binding of NFAT5
and ChREBP in the MIOX promoter. Using ARIs may slow down,
or prevent the development of diabetic nephropathy by inhibiting
both the polyol and glucuronate–xylulose pathways to decrease
the production of sorbitol and to restore the MI levels within cells,
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